New Leaf Venture Partners

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Kyruus delivers proven provider search and scheduling solutions that help hospitals and health systems match patients with the providers best suited to care for them. The ProviderMatch suite of solutions—for consumers, access centers, and referral networks—enables a consistent patient experience across multiple points of access, while aligning provider supply with patient demand. The company’s proprietary provider data management platform forms the foundation of its solutions, powering them with accurate data by coupling data processing with administrative applications. Kyruus was founded in 2010 and is headquartered in Boston, Massachusetts.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada. Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

CardioKinetix, Inc. develops transcatheter implants. Its portfolio includes Parachute, a ventricular partitioning device that intends to treat heart failure resulting from a heart attack in patients by improving the overall cardiac function. The company’s Parachute is deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. It serves customers primarily in the United States, France, Germany, Latvia, Portugal, Serbia, Slovenia, the Netherlands, and the United Kingdom. The company was incorporated in 2002 and is headquartered in Menlo Park, California.

Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With business and development operations based in Boston, and dedicated research capabilities in close proximity to the University of Kansas, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions. The device is designed to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Access Closure, Inc., a medical device company, provides access site management products to address the complex challenge of vascular closure during interventional and diagnostic procedures. The company's products include Mynx delivery system, a vascular closure device that seals the arteriotomy using a water-soluble and extravascular sealant, which expands in the tissue tract by absorbing blood and subcutaneous fluids. Access Closure, Inc. was founded in 2002 and is based in Mountain View, California.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. The company was founded in 2003 and is based in Malvern, Pennsylvania.

Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches. Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required. Akili is based in Boston, Massachusetts.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Karyopharm Therapeutics is a biopharmaceutical company focusing on the development of novel drugs for the treatment of cancer, inflammation and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and to evaluate them in subsequent human clinical studies.

Founded in 2000, XDx, Inc. is a molecular diagnostics company based in Brisbane, CA, USA. XDx applies modern genomics technologies to the development of molecular diagnostic assays that translate a patient's immune status into clinically actionable information. XDx has one marketed product, AlloMap Molecular Expression Testing, and other products under development. The proprietary molecular expression technology used by XDx to develop AlloMap testing for heart transplant patient management may be applicable to the post-transplant management of recipients of other organs. The application of gene expression testing to other diseases that involve the activity of the immune system, such as autoimmune and chronic inflammatory diseases, is also being explored.

QPID Health, Inc., a healthcare IT software company, delivers a health record intelligence platform and Web-based applications that enable healthcare institutions and clinicians to gain insights from electronic health records (EHRs). The company operates Queriable Programmable Inference Dossier (QPID), an intelligence system for the EHR that permits the creation of clinician-directed queries, analytics, and reporting abilities in real time and at the point of care. Its QPID platform aggregates EHR data, prepares information for search, and delivers meaningful information to clinicians and administrators in Web-based applications. QPID Health, Inc. is based in Boston, Massachusetts with locations in Boston, Massachusetts; and San Diego, California. As of February 26, 2016, QPID Health, Inc. operates as a subsidiary of eviCore healthcare.

Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

BrightInsight provides a digital health platform for bio-pharma and med-tech. Its IoT platform is built under a quality management system to support and optimize regulated drugs, devices, and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. BrightInsight was founded in 2017 and is headquartered in San Jose, California.

Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions. The device is designed to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.

Asimily, Inc. develops a vertical specific distributed analytics software solution. The company offers healthcare specific management platform with non-invasive information technology and risk management for medical devices and vendors. The company's product portfolio of functionality includes managing the system of devices, helps predict the device posture across security and operational use cases, and ensures devices behave as expected. Asimily, Inc. was formerly known as Assimily, Inc. The company was incorporated in 2017 and is headquartered in Sunnyvale, California.

Cleerly is a healthcare company whose mission is to create digital care pathways to prevent heart attacks. The company develops a new standard for coronary artery disease by integrating quality clinical science with the latest-generation AI, in order to offer actionable clinical insights to every stakeholder in the heart care pathway. Through these data-driven solutions, the company aims to provide a comprehensive solution for cardiovascular disease evaluation that offers value to the healthcare system and improves heart health for patients at risk of heart attacks.

ARINE INC. develops a clinical learning and analytic response engine for data-driven clinical services to patients and their families. Its solution provides tailored and action-oriented medication recommendations and education to patients and their care teams, as well as engages in ongoing review and monitoring for timely follow-up, and outcomes evaluation and reporting. The company was incorporated in 2017 and is based in San Francisco, California.

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSK”). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.

Saniona is a research and development company with low burn rate, a world class team and high ambitions.

DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

WorldHeart is a public company headquartered in Salt Lake City, Utah (USA), with additional offices located in Oakland, California (USA), and in Herkenbosch (The Netherlands). Its registered office is Delaware, USA. Its stock trades on the NASDAQ National Market (ticker symbol: WHRT).

BrightInsight provides a digital health platform for bio-pharma and med-tech. Its IoT platform is built under a quality management system to support and optimize regulated drugs, devices, and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. BrightInsight was founded in 2017 and is headquartered in San Jose, California.

Altura Medical is an emerging medical device company based in Menlo Park, CA that is developing a next generation endograft technology to treat abdominal aortic aneurysms (“AAA”) and other related disease states. Development of the company’s highly differentiated technology is led by an experienced management team and supported by a prestigious syndicate of venture capital investors.

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Transcept Pharmaceuticals, Inc. uses its proprietary delivery system to enhance the penetration of drugs, significantly speeding their onset of action. Transcept is developing rapid-acting versions of several major market pharmaceuticals. Hamilton co-invested in the company's first institutional round of funding alongside Montreaux Equity Partners, Peninsula Equity Partners and Vivo Ventures. Investors in subsequent financing rounds include these firms, and New Leaf Venture Partners, Interwest Partners and New Enterprise Associates.

KitCheck is a provider of a cloud software platform used to offer automated hospital pharmacy kit processing and medication tracking. The company provides cloud-hosted software combined with IoT technology to reduce kit replenishment time by 72-96% while simultaneously delivering higher accuracy and eliminating errors. In addition, the Narc Check product streamlines recording, waste reconciliation, and billing for medications used in the operating room. Kit Check is used across hundreds of hospitals in the U.S. and Canada and tracks over 90% of all kit medication volume in the industry that is digitally tracked.

Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Rallybio, LLC, a biopharmaceutical company, develops transformative therapies for patients with severe and rare disorders. Its lead product candidate, RLYB211, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. Its drugs focus on antibodies, small molecules, and engineered proteins. The company was founded in 2018 and is based in New Haven, Connecticut.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused by gram-positive and gram-negative pathogens.

Aesthetic Sciences Corp a Palo Alto, Calif.-based developer of injectable filler products for soft tissue augmentation.

ProteoGenix engages in the development and commercialization of diagnostic testing products for the maternal-fetal health community. Its products include non-invasive diagnostics tests to detect intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and down syndrome. ProteoGenix, Inc. was founded in 2002 and is based in Costa Mesa, California with additional offices in Beaverton, Oregon; and Orange County, California.

TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

IlluminOss Medical, Inc. is a commercial-stage medical device company offering a unique, minimally invasive technology for fracture repair and stabilization. The Company utilizes a light-curable polymer contained within an expandable balloon to create a patient-conforming intramedullary implant for bone stabilization. The revolutionary, minimally invasive technology is particularly applicable for repair and treatment of patients with osteoporotic and compromised bone. The IlluminOss system is CE-marked and FDA-cleared for a variety of anatomical sites, with further indications pending.

Qlaris Bio, Inc., a biotechnology company, develops therapies for debilitating ophthalmic diseases. It offers QLS-101, a therapy to reduce intraocular pressure. Qlaris Bio, Inc. was founded in 2017 and is headquartered in Wellesley, Massachusetts.

Oriel Therapeutics is a specialty pharmaceutical company developing and commercializing products to improve respiratory care. Combining an experienced product development team and a growing portfolio of innovative drug delivery technologies, Oriel is focused on delivering compelling patient options for the treatment of asthma and COPD.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Awarepoint Corporation provides a cloud-based real-time locating system that delivers to track locations. The company offers analytical tools to transform real-time location data into operational intelligence; and managed services that include analysis, configuration, installation, validation, and training. It also provides a Temperature Monitoring System that enables medical facilities to maintain compliance to CDC Vaccines for Children program guidelines and ensure that vaccines are monitored within the recommended temperature range. The company serves clients in healthcare, manufacturing, retail, and other industries. Awarepoint Corporation was formerly known as NeverLost Networks, Inc. The company was founded in 2002 and is based in San Diego, California.

Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are dedicated to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers, and society.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Kyruus delivers proven provider search and scheduling solutions that help hospitals and health systems match patients with the providers best suited to care for them. The ProviderMatch suite of solutions—for consumers, access centers, and referral networks—enables a consistent patient experience across multiple points of access, while aligning provider supply with patient demand. The company’s proprietary provider data management platform forms the foundation of its solutions, powering them with accurate data by coupling data processing with administrative applications. Kyruus was founded in 2010 and is headquartered in Boston, Massachusetts.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

CardioKinetix, Inc. develops transcatheter implants. Its portfolio includes Parachute, a ventricular partitioning device that intends to treat heart failure resulting from a heart attack in patients by improving the overall cardiac function. The company’s Parachute is deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. It serves customers primarily in the United States, France, Germany, Latvia, Portugal, Serbia, Slovenia, the Netherlands, and the United Kingdom. The company was incorporated in 2002 and is headquartered in Menlo Park, California.

iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. Zio® Patch is the smallest, lightest, least conspicuous cardiac arrhythmia diagnostic available and is indicated for up to 14-day monitoring.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversible covalent platform.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Tioga Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of pruritus. It offers Asimadoline, an orally active kappa opioid receptor agonist used for the treatment of pruritus or itching associated with atopic dermatitis. The company was incorporated in 2005 and is based in San Diego, California.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

TigerConnect is a provider of clinical communication solutions, TigerConnect helps physicians, nurses, and other staff communicate and collaborate more effectively, accelerating productivity, reducing costs, and improving patient outcomes. Trusted by more than 4,000 healthcare organizations, TigerConnect maintains 99.99% uptime and processes over 10 million messages each day. Its category-leading product innovations and advanced integrations with critical hospital systems deliver high value for hospitals and large health systems. Their commitment to client success is reflected in their broad support organization that works directly with clients at every stage to streamline communication workflows and achieve the highest possible ROI. The company was incorporated in 2010 and is headquartered in Santa Monica, California.

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette's disorder. Catalyst is developing Firdapse™ (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse™ has the potential to treat other neuromuscular disorders such as congenital myasthenic syndrome and some cases of myasthenia gravis that are refractory to currently approved therapies.

Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. The company was founded in 2003 and is based in Malvern, Pennsylvania.

Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With business and development operations based in Boston, and dedicated research capabilities in close proximity to the University of Kansas, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.

Aureon Laboratories is a life sciences company dedicated to enabling the advancement of predictive and personalized cancer treatment. Aureon provides objective, actionable information allowing patients and physicians to make more-informed treatment decisions through its prostate diagnostic tools.

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2α, or PGF2α receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

IRLAB is a Swedish drug discovery and development company providing novel treatments for disorders of the brain. IRLAB is engaged in programmes targeting core dysfunctions in Parkinson’s disease and dementias. IRLAB has identified, and is currently engaged in clinical development of, two novel compounds aimed at offering improved clinical benefit for patients with Parkinson’s disease.

BrightInsight provides a digital health platform for bio-pharma and med-tech. Its IoT platform is built under a quality management system to support and optimize regulated drugs, devices, and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. BrightInsight was founded in 2017 and is headquartered in San Jose, California.

Direct Flow Medical is a medical device company developing a percutaneous aortic tissue valve prosthesis to provide patients requiring treatment of cardiac valve insufficiency with a safe and effective percutaneous option. Approximately 1.2 million people over the age of 65 have calcified aortic valves, yet only an estimated 150,000 are surgically treated each year.

KitCheck is a provider of a cloud software platform used to offer automated hospital pharmacy kit processing and medication tracking. The company provides cloud-hosted software combined with IoT technology to reduce kit replenishment time by 72-96% while simultaneously delivering higher accuracy and eliminating errors. In addition, the Narc Check product streamlines recording, waste reconciliation, and billing for medications used in the operating room. Kit Check is used across hundreds of hospitals in the U.S. and Canada and tracks over 90% of all kit medication volume in the industry that is digitally tracked.

Curasen Therapeutics Inc. operates as a biotechnology company which develops therapies to treat neurodegenerative diseases. It also develops small molecule drugs that targets a novel mechanism in the brain to restore function, improve symptoms, and modify diseases, such as less common (orphan) neurodegenerative disorders, and Parkinson's disease and Alzheimer's disease. The company was incorporated in 2016 and is based in Los Altos, California.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Tioga Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of pruritus. It offers Asimadoline, an orally active kappa opioid receptor agonist used for the treatment of pruritus or itching associated with atopic dermatitis. The company was incorporated in 2005 and is based in San Diego, California.

Karus Therapeutics Limited is a biopharmaceutical company that develops medicines for cancer. Its portfolio includes orally-active small molecule drugs, including KA2237, a dual-selective inhibitor of PI3K isoforms, such as p110ß and p110d for treating hematological and solid tumors; and KA2507 (HDAC6) for PD-L1 expressing tumors. The company was incorporated in 2005 and is based in Oxfordshire, United Kingdom.

Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

ProteoGenix engages in the development and commercialization of diagnostic testing products for the maternal-fetal health community. Its products include non-invasive diagnostics tests to detect intraamniotic infection, neonatal sepsis, preterm birth, preeclampsia, and down syndrome. ProteoGenix, Inc. was founded in 2002 and is based in Costa Mesa, California with additional offices in Beaverton, Oregon; and Orange County, California.

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. AiCure's platform has the potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment. It was founded in 2010 and is headquartered in New York.

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. AiCure's platform has the potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment. It was founded in 2010 and is headquartered in New York.

Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, MA.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. The company was founded in 2003 and is based in Malvern, Pennsylvania.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Neurana Pharmaceuticals, Inc. is a pharmaceutical company that develops treatment for neuromuscular conditions, including acute and painful muscle spasms of the neck and back. The company provides Tolperisone, a therapeutic compound that treats musculoskeletal conditions, including neuromuscular spasms and spasticity without sedation. The company was formerly known as Katama Pharmaceuticals Inc. Neurana Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in San Diego, California.

Truveris brings transparency to the prescription drug ecosystem through data-driven innovations. Truveris’ platform offers customers – from the individual patient to employers, retailers, pharmacy benefits stakeholders, and manufacturers – the data and insights they need to effectively and efficiently manage rising costs and market access challenges. Based in Manhattan, Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital.

Treato Ltd. operates Treato, provides social health patient intelligence solutions. The company offers health information platform that aggregates patient experiences from the Internet; and organizes them into usable insights for patients, healthcare professionals, pharma companies, and other healthcare organizations. Its Treato platform collects data from healthcare social media sites and forums; analyzes the information; and provides a window into patients’ thoughts and attitudes. The company also provides Treato Pharma, a brand intelligence service for pharma marketers and agencies to provide analytics and insights into patients’ thoughts and attitudes. Its Treato Pharma also interprets the patient voice, understands patient behaviors, gains competitive insights, extracts the right messages, expends effort into the right places, and engages in real time. Treato Ltd. was founded in 2008 and is based in Yehud, Israel.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).

Truveris brings transparency to the prescription drug ecosystem through data-driven innovations. Truveris’ platform offers customers – from the individual patient to employers, retailers, pharmacy benefits stakeholders, and manufacturers – the data and insights they need to effectively and efficiently manage rising costs and market access challenges. Based in Manhattan, Truveris is backed by Canaan Partners, New Leaf Venture Partners, Tribeca Venture Partners, New Atlantic Ventures and First Round Capital.

AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time. AiCure's platform has the potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment. It was founded in 2010 and is headquartered in New York.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases. WaVe maintains R&D facilities in Boston and Japan and was founded by two world-renowned scientific leaders, Gregory Verdine and Takeshi Wada. Dr. Verdine is an Erving Professor of Chemistry in the Harvard University Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology. Dr. Wada is a professor at Tokyo University of Science, Faculty of Pharmaceutical Sciences and Department of Medicinal and Life Science.

Rallybio, LLC, a biopharmaceutical company, develops transformative therapies for patients with severe and rare disorders. Its lead product candidate, RLYB211, is in development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. Its drugs focus on antibodies, small molecules, and engineered proteins. The company was founded in 2018 and is based in New Haven, Connecticut.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Intrinsic Therapeutics is a medical device company that develops therapies for treating disc herniations in the spine for discectomy patients. It offers Barricaid anular prosthesis that allows the direct reconstruction of weakened and ruptured annulus and soft tissues of the spine. The company also offers spinal implants to treat the causes of sciatica and low back pain. It serves surgeons and patients. The company was formerly known as Intrinsic Orthopedics and changed its name to Intrinsic Therapeutics in January 2003. Intrinsic Therapeutics was founded in 2000 and is based in Woburn, Massachusetts.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Oxford Immunotec is a medical diagnostics company developing novel new tests for various diseases based on its innovative, patented T cell measurement technology. The company's first product is a TB test that diagnoses latent TB infection ( LTBI ) and TB disease. T-SPOT®.TB is an interferon gamma release assay ( IGRA ) which are designed to replace the century old Mantoux skin test ( TST ).

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Renovacor, Inc., a biopharmaceutical company, develops therapies for the treatment of cardiovascular disease. It develops a gene therapy, which helps to restore cardiac function in patients with heart failure. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.

ReShape Medical Inc. provides a non-surgical weight loss procedure that helps people to lose weight. The company’s ReShape procedure combines two intragastric balloons with a one-year personalized weight loss program to help patients with mild to moderate obesity (BMI 30-40). The company’s ReShape is provided at medical weight loss centers. ReShape Medical Inc. was formerly known as Abdominis, Inc. The company was founded in 2005 and is based in San Clemente, California. As of October 2, 2017, ReShape Medical Inc. operates as a subsidiary of EnteroMedics Inc.

IlluminOss Medical, Inc. is a commercial-stage medical device company offering a unique, minimally invasive technology for fracture repair and stabilization. The Company utilizes a light-curable polymer contained within an expandable balloon to create a patient-conforming intramedullary implant for bone stabilization. The revolutionary, minimally invasive technology is particularly applicable for repair and treatment of patients with osteoporotic and compromised bone. The IlluminOss system is CE-marked and FDA-cleared for a variety of anatomical sites, with further indications pending.

Afferent Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It develops medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. The company’s AF-219, a compound that completed two Phase 1 clinical studies. Afferent Pharmaceuticals, Inc. was founded in 2009 and is based in San Mateo, California.

Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Interlace Medical, Inc. is focused on designing and developing devices for the Interventional Gynecologist to perform office-based procedures to treat diseases and conditions traditionally requiring surgery in the operating room.

Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. The company was founded in 2003 and is based in Malvern, Pennsylvania.

Spiracur Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome for patients and clinicians. Spiracur strives to develop products that are truly patient-centric.

KitCheck is a provider of a cloud software platform used to offer automated hospital pharmacy kit processing and medication tracking. The company provides cloud-hosted software combined with IoT technology to reduce kit replenishment time by 72-96% while simultaneously delivering higher accuracy and eliminating errors. In addition, the Narc Check product streamlines recording, waste reconciliation, and billing for medications used in the operating room. Kit Check is used across hundreds of hospitals in the U.S. and Canada and tracks over 90% of all kit medication volume in the industry that is digitally tracked.

iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. Zio® Patch is the smallest, lightest, least conspicuous cardiac arrhythmia diagnostic available and is indicated for up to 14-day monitoring.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

GluMetrics, Inc., a medical device company, develops tools that enable clinicians to implement a care paradigm for critically ill patients. Its products include GluCath, an intravascular continuous glucose monitoring system to measure blood sugar. The company was founded in 2005 and is based in Irvine, California.

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. It was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Spiration, Inc., doing business as Olympus Respiratory America, develops medical devices for the treatment of air leaks and lung diseases. The company was founded in 1999 and is based in Redmond, Washington. As of 2010, Spiration, Inc. operates as a subsidiary of Olympus America Inc.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. The company primarily focuses on the development of therapies for hepatitis C virus (HCV) infection. Its portfolio of products includes pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride intended for targeting NS5A and NS5B proteins of HCV. The company was founded in 2006 and is based in San Francisco, California.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

iRhythm provides innovative and cost-effective diagnostic monitoring solutions that facilitate early diagnosis and treatment decisions, with the goal of ultimately improving patient health outcomes and reducing wasteful healthcare spending. Its flagship product, the Zio® Patch, is designed to optimize and simplify the diagnosis of cardiac arrhythmias. Zio® Patch is the smallest, lightest, least conspicuous cardiac arrhythmia diagnostic available and is indicated for up to 14-day monitoring.

Spine Wave, Inc. manufactures and markets medical equipment for the treatment of spinal disorders. It offers expandable PEEK spacers and expandable interbody devices for posterior surgery; pivoting spacer systems; lateral spacer systems, XDL expandable devices, and lateral access systems for lateral stabilization; Leva PX, an expandable interbody device for the treatment of spinal disorders; GraftMag Graft Delivery System to deliver large amounts of bone graft; and fixation products, such as spine systems for treating degeneration, deformity, tumor, and trauma of the thoracolumbar spine, as well as adjacent level systems. The company also offers anterior cervical plate systems that provide stabilization as an adjunct to spinal fusion from C2-C7 through anterior screw fixation; and cervical spacer systems to treat degenerative disc disease from C2-T1. It offers its products through distributors. Spine Wave, Inc. was founded in 2001 and is based in Shelton, Connecticut.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Aureon Laboratories is a life sciences company dedicated to enabling the advancement of predictive and personalized cancer treatment. Aureon provides objective, actionable information allowing patients and physicians to make more-informed treatment decisions through its prostate diagnostic tools.

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. The company primarily focuses on the development of therapies for hepatitis C virus (HCV) infection. Its portfolio of products includes pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride intended for targeting NS5A and NS5B proteins of HCV. The company was founded in 2006 and is based in San Francisco, California.

Technology Will Save Us Ltd. develops DIY gadget kits and hardware, activities, and online resources for families, educators, and young people to make, play, code, and invent using technology. Its kits include a handheld games console, an electronic synthesizer, conductive dough, a DIY speaker kit, moisture sensors, and an open-source electronics platform based on hardware and software. The company serves classrooms, after school clubs, or home schools. It offers its products through its kiosks in the United Kingdom and internationally. The company also offers its products online. Technology Will Save Us Ltd. was incorporated in 2011 and is based in London, United Kingdom.

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Kalidex Pharmaceuticals, Inc. manufactures pharmaceuticals. The company was incorporated in 2010 and is based in Menlo Park, California.

Access Closure, Inc., a medical device company, provides access site management products to address the complex challenge of vascular closure during interventional and diagnostic procedures. The company's products include Mynx delivery system, a vascular closure device that seals the arteriotomy using a water-soluble and extravascular sealant, which expands in the tissue tract by absorbing blood and subcutaneous fluids. Access Closure, Inc. was founded in 2002 and is based in Mountain View, California.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Spiracur Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome for patients and clinicians. Spiracur strives to develop products that are truly patient-centric.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers. Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

CardioKinetix, Inc. develops transcatheter implants. Its portfolio includes Parachute, a ventricular partitioning device that intends to treat heart failure resulting from a heart attack in patients by improving the overall cardiac function. The company’s Parachute is deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. It serves customers primarily in the United States, France, Germany, Latvia, Portugal, Serbia, Slovenia, the Netherlands, and the United Kingdom. The company was incorporated in 2002 and is headquartered in Menlo Park, California.